Refametinib Completed Phase 2 Trials for Hepatocellular Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01915602Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
NCT01915589Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
NCT01204177Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.